Peninsula biotech company Vivace Therapeutics has raised $35 million to push mesothelioma drug toward late-stage trial.

HSBC Saudi Arabia, as a global coordinator and a bookrunner for institutional subscription by Impact46 in its capacity as the ...

(HNIs) and family offices are flocking to AIFs in 2025 for higher returns and diversification, with assets soaring 36% to ...

Top 10 Stock Picks. In this article, we are going to take a look at where Alphabet Inc. (NASDAQ:GOOG) stands against other ...

A new report projects that the generative AI boom in the Bay Area will continue its exponential growth over the next 24 ...

The discussion unpacked the current state of AI investing, the risks of overvaluation, and what it will take for AI startups ...

The technologies behind these applications exist thanks to GPS satellites—one example of military technology that was ...

Cybersecurity’s evolution has gone beyond the outdated, with leaders like Nick Raziborsky steering the industry toward more ...

Last year, venture capital-backed quantum startups raised $1.9 billion in 62 rounds, according to Crunchbase data. The dollar ...

Several tech companies including CoreWeave, Klarna, and Discord are setting out to go public sometime over the second quarter ...

Imprint’s cloud-based ledger system allows retailers to micro-target rewards. Does it have a shot against big branded-card ...